8-K: Myriad Genetics Reports Q2 Loss Amid Impairment

Myriad Genetics reported a significant net loss in Q2 2025 due to impairment charges, while raising full-year revenue guidance and securing a new credit facility.

Summary

• Second quarter 2025 revenue reached $213.1 million, a 1% increase year-over-year, or 5% excluding previously discussed headwinds of $9.5 million.
• The company reported a GAAP net loss of $330.5 million, or $(3.57) per share, primarily due to $316.7 million in non-cash impairment charges.
• Adjusted EPS for Q2 2025 was $0.05.
• Gross margin improved to 71.2%, up over 160 basis points year-over-year, driven by product mix, improved average revenue per test, and laboratory efficiencies.
• Full-year 2025 revenue guidance was raised to a range of $818 $828 million, from the prior range of $807 $823 million.
• Full-year 2025 adjusted EPS guidance was reiterated at $(0.02) $0.02.
• A new $200 million credit facility was entered into on July 31, 2025, to enhance financial flexibility.
• Total test volumes decreased 1% year-over-year to 384,000 in Q2 2025.
• Hereditary cancer testing revenue in Oncology grew 9% year-over-year, with MyRisk with RiskScore testing volume up 14% year-over-year.
• Prenatal testing revenue increased 7% year-over-year, despite an 8% decrease in volume due to friction from a new order management system implementation.
• Pharmacogenomics (GeneSight) revenue decreased 12% year-over-year, impacted by UnitedHealthcare's discontinuation of coverage for multi-gene panel pharmacogenetic testing.

Sentiment

Score: 5

Explanation: The sentiment is mixed. Positive aspects include raised revenue guidance, strong gross margin, and a new credit facility. However, these are significantly offset by a large GAAP net loss driven by a substantial non-cash impairment charge, indicating a decline in market capitalization and asset value, alongside operational friction in prenatal testing and ongoing payer coverage challenges for GeneSight.

Positives

• Second quarter 2025 revenue increased by 1% year-over-year, and 5% excluding specific headwinds.
• Hereditary cancer testing revenue in Oncology grew 9% year-over-year, with volume up 10%, indicating strong performance in a key segment.
• MyRisk with RiskScore testing volume in oncology grew 14% year-over-year, highlighting adoption of a key product.
• Gross margin improved significantly to 71.2%, up over 160 basis points year-over-year, reflecting operational efficiencies and favorable product mix.
• Full-year 2025 revenue guidance was raised, indicating an improved outlook for top-line performance.
• Adjusted operating income for Q2 2025 was $8.6 million, demonstrating underlying operational profitability despite GAAP losses.
• A new $200 million credit facility was secured, enhancing financial flexibility and supporting growth initiatives.
• Prenatal testing revenue grew 7% year-over-year, driven by expanding payer coverage for Foresight Expanded Carrier Screen.

Negatives

• GAAP net loss for Q2 2025 was $330.5 million, or $(3.57) per share, a substantial loss.
• A significant non-cash impairment charge of $316.7 million was recorded, primarily due to a decline in Myriad's market capitalization.
• Total test volumes decreased 1% year-over-year in Q2 2025.
• Tumor profiling revenue decreased 4% year-over-year, primarily due to the divestiture of the European EndoPredict business.
• Prenatal testing volume decreased 8% year-over-year due to friction from a new order management system implementation.
• Pharmacogenomics (GeneSight) revenue decreased 12% year-over-year, significantly impacted by UnitedHealthcare's discontinuation of coverage.
• Cash flow used in operations was $13.6 million in Q2 2025, indicating negative operational cash generation.

Risks

• Sales and profit margins of existing tests may decline.
• Inability to operate the business on a profitable basis.
• Failure to achieve certain revenue growth targets or generate sufficient revenue from existing or new tests to be profitable.
• Changes in governmental or private insurers' coverage and reimbursement levels for tests, including UnitedHealthcare's coverage decisions for GeneSight.
• Increased competition and the development of new competing tests.
• Inability to develop or achieve commercial success for additional tests in a timely manner.
• Inability to secure additional financing to fund the business in a timely manner or on favorable terms.
• Inability to successfully develop new markets or channels for tests.
• Termination or inability to maintain satisfactory terms for licenses to technology underlying tests.
• Delays or other problems with operating laboratory testing facilities.
• Public concern over genetic testing in general or the company's tests in particular.
• Regulatory requirements or enforcement changes in the United States and foreign countries, and changes in healthcare system structure or payment systems.
• Inability to obtain new corporate collaborations or licenses, or acquire/develop new technologies or businesses on satisfactory terms.
• Inability to successfully integrate and derive benefits from licensed, acquired, or developed technologies/businesses.
• Inaccuracy of projections or estimates about the potential market opportunity for current and future products.
• Inability to protect proprietary technologies or infringement by third parties.
• Patent-infringement claims or challenges to the validity of patents.
• Changes in intellectual property laws covering tests, patents, or enforcement.
• Security breaches, loss of data, and other disruptions, including cyberattacks.
• Inability to keep pace with rapid technology changes in the industry or properly leverage new technologies.
• Inability to comply with financial or operating covenants under credit or lending agreements.
• Inability to maintain effective disclosure controls and procedures and internal control over financial reporting.
• Current and future investigations, claims, or lawsuits, including derivative claims, product or professional liability claims.

Future Outlook

Myriad Genetics is updating its long-range growth strategy to focus on the Cancer Care Continuum, aiming to accelerate growth and profitability. This includes expanding its test portfolio into therapy selection, immuno-oncology therapy response monitoring, and Molecular Residual Disease (MRD), with an early access launch of its proprietary MRD test planned for the first half of 2026. The company also plans to commercially launch FirstGene Multiple Prenatal Screen in 2026 and an AI-driven prostate cancer test in Q1 2026. Over the next five years, Myriad Genetics targets high single-digit to low double-digit revenue growth and increased profitability by maintaining financial discipline and growing revenue faster than operating expenses.

Management Comments

• "We delivered solid second-quarter results, driven by continued strength in hereditary cancer testing in oncology, improving momentum in hereditary cancer testing for unaffected individuals, and favorable pricing trends supported by mix and our ongoing efforts to expand payer coverage."
• "Our disciplined approach to expense management contributed to our improved profitability while we continued to invest in strategic drivers to enable long-term growth."
• "We have made significant progress on updating our strategy and intend to accelerate growth by focusing future investments on more comprehensively serving screening and diagnostic applications across the Cancer Care Continuum while being disciplined on driving targeted profitable growth from our other businesses."
• "To help support our next chapter, we have partnered with OrbiMed in a non-dilutive financing, providing meaningful support for Myriad Genetics' long-term goals."
• "As we begin to implement our updated strategy, while continuing to strengthen our organization and execution, I'm confident in our ability to achieve sustained value creation going forward."

Industry Context

Myriad Genetics operates in the molecular diagnostic testing and precision medicine industry, with a strong focus on cancer care, women's health, and pharmacogenomics. The strategic shift towards a more comprehensive Cancer Care Continuum approach aligns with broader industry trends emphasizing personalized medicine and integrated diagnostic solutions across the patient journey. The company's investment in Molecular Residual Disease (MRD) testing and AI-driven diagnostics reflects the industry's move towards more sensitive and data-driven diagnostic tools. Challenges like payer coverage decisions (e.g., UnitedHealthcare's stance on multi-gene panel pharmacogenetic testing) highlight ongoing reimbursement pressures and the need for robust clinical utility data in the diagnostics sector.

Comparison to Industry Standards

• The company's gross margin of 71.2% is strong and indicates efficient operations, which is competitive within the molecular diagnostics industry, where high margins are often achievable for proprietary tests.
• The significant non-cash impairment charge of $316.7 million due to a decline in market capitalization suggests that the company's valuation has underperformed relative to its historical asset values, which could be a concern compared to more stable or growing peers in the biotech/diagnostics space.
• The strategic focus on the Cancer Care Continuum, including the development of an ultra-sensitive Precise MRD test and an AI-driven prostate cancer test (in partnership with PATHOMIQ), positions Myriad Genetics to compete with other diagnostic companies like Guardant Health (MRD testing) and Exact Sciences (cancer diagnostics) that are also expanding their portfolios in these high-growth areas.
• The challenge with UnitedHealthcare's coverage for GeneSight highlights a common industry hurdle where diagnostic companies must continuously demonstrate clinical utility and cost-effectiveness to secure and maintain favorable payer coverage, a challenge faced by many in the pharmacogenomics and broader diagnostics market.

Stakeholder Impact

• Shareholders: Experienced a significant GAAP net loss due to impairment, impacting equity value, but the company aims for sustained value creation through strategic growth.
• Employees: Increased investment in R&D and commercial capabilities suggests continued focus on innovation and growth, potentially benefiting employees.
• Customers: Plans to enhance customer digital experience and expand test portfolios (e.g., new prenatal tests, MRD test) aim to improve patient care and service offerings.
• Suppliers: No direct impact mentioned, but operational efficiencies and disciplined cost management could influence supplier relationships.
• Creditors: The new $200 million credit facility provides enhanced financial flexibility, potentially improving the company's ability to meet its obligations.

Next Steps

• Complete the updated long-range growth strategy over the next several months.
• Increase investment in R&D and enhance commercial capabilities and customer digital experience.
• Leverage strategic partnerships and Biopharma service synergies to unlock new growth drivers.
• Commercially launch the first AI-driven prostate cancer test in partnership with PATHOMIQ in the first quarter of 2026.
• Initiate early access launch of the proprietary, ultra-sensitive MRD test in the first half of 2026.
• Commercially launch FirstGene Multiple Prenatal Screen in 2026.

Key Dates

Recommendation

While Myriad Genetics demonstrated positive operational momentum in key segments like hereditary cancer testing and raised its revenue guidance, the substantial non-cash impairment charge leading to a significant GAAP net loss is a major concern, reflecting a decline in market capitalization. The new credit facility provides liquidity, but the underlying profitability remains low on an adjusted basis. The strategic pivot to the Cancer Care Continuum and future test launches offer long-term potential, but current operational challenges (e.g., prenatal volume decrease due to system friction, GeneSight coverage issues) and the large impairment indicate ongoing volatility and execution risks. A 'hold' recommendation is appropriate as investors should monitor the successful implementation of the new strategy and the company's ability to translate revenue growth into sustainable GAAP profitability before considering a stronger position.

Keywords

Molecular Diagnostics, Precision Medicine, Genetic Testing, Cancer Care Continuum, Hereditary Cancer, Pharmacogenomics, Prenatal Testing, MyRisk, GeneSight, MRD Test, Oncology, Women's Health, Biopharma Services, SEC Filing, Earnings Report